Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.

Cancer medicine - 1 Mar 2020

Cheng He, Luo Guopei, Jin Kaizhou, Fan Zhiyao, Huang Qiuyi, Gong Yitao, Xu Jin, Yu Xianjun, Liu Chen

Abstract excerpt

PURPOSE: Kras mutation and abnormal immune status are associated with pancreatic cancer development and progression. In this study, we evaluated the Kras mutation status in circulating tumor DNA and circulating T cell subsets in a cohort of advanced pancreatic cancer patients. METHODS: Samples were retrospectively obtained from a series of 210 pathological advanced pancreatic cancer patients between 2012 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Kaplan-Meier Estimate

Share to Neoplasm Staging

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to T-Lymphocytes, Regulatory

Source

Open in PubMed Open full text

Identifiers

PMID: 32017404
DOI: 10.1002/cam4.2895
PMCID: PMC7064028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.PMID 32017404Read ↗

KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancerSemantic proximity Read ↗

Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes.Semantic proximity Read ↗

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D MutationSemantic proximity Read ↗

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer PatientsSemantic proximity Read ↗

Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer.Semantic proximity Read ↗

Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer.Semantic proximity Read ↗

KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.Semantic proximity Read ↗

Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.Semantic proximity Read ↗

Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.Semantic proximity Read ↗

Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.Semantic proximity Read ↗

Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.